Laboratory for Advanced Medicine & Health

Laboratory for Advanced Medicine & Health Group (LAMH) is an AI-driven cancer screening and early diagnosis innovation company founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier". LAMH was founded by international business leaders, top scientists and authoritative doctors with the concept of "making cancer screening more accurate, earlier and easier", and has raised over RMB 1 billion since its inception. As a global leader in early screening and diagnosis of cancer, LAMH has collaborated with many top cancer centers, universities and their affiliated hospitals, published relevant research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and established a full product pipeline for early screening and diagnosis of liver cancer, intestinal cancer, lung cancer and pan-cancer. LAMH is committed to providing a full lifecycle service with the help of AI-driven technology, combined with genomics and clinical medicine theories.

LAMH, an independent entity in China, is headquartered in the central business district of Pazhou, Guangzhou, with a R&D and registration center in Beijing Economic and Technological Development Zone, and a Southern and Northern Medical Laboratory (ICL) meeting PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang, respectively. There is an IVD GMP factory in Guangzhou Science City that has passed the NMPA system assessment,Helio Genomics is a U.S. independent entity headquartered in Irvine, California, with CLIA - and CAP-certified central laboratories in Indiana.


Making cancer screening

more accurate earlier and easier


Technology-driven global leader

in early cancer screening


Result-driven, customer-centric


Core Technology
Technology-Driven Global Leader In Early Screening
And Diagnosis Of Cancer
The world's first large scale liver cancer early screening research results based on cfDNA methylation technology, pioneering the use of cfDNA methylation for early cancer screening.
LAMH research results show that methylation markers can be used effectively in the diagnosis and prognosis of breast, colorectal, liver and lung cancers.
CHALM-cell heterogeneity-adjusted methylation quantitative analysis method.
Research published in the Journal of the American Association for the Study of Liver Cancer has shown that the LAMH HelioLiver Test, a liver cancer early screening product, can accurately detect early stage liver cancer.
IvyGene® Liver
Hepatocellular carcinoma gene
methylation test
IvyGene®Liver Plus
Hepatocellular carcinoma gene
methylation test
lvyGene® PLUS
Early and accurate cancer screening
Core Team
Zeyue Zhang
Chairman / CEO
Zeyue Zhang
Chairman / CEO

Mr. Zeyue Zhang has a rich background in Business, clinical medicine and biotechnology in the gene industry; He has management experience in start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He has worked in well-known domestic gene companies such as BGI, BoA, Roche and Novartis, as well as the sales department of well-known multinational pharmaceutical companies.

Bachelor of Medicine, Southern Medical University;
Executive Master of Business Administration (EMBA) from China Europe International Business School (CEIBS).

Shu Li
Founder / Co-Chairman
Shu Li
Founder / Co-Chairman

Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.

Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.

Company History
World's First Methylation Technology Company
LAMH Receives UCSD's World's First Methylation Cancer Screening Technology
LAMH Was Officially Established
Awarded PCT patent
Including solid tumors, colon cancer, lung cancer, leukemia, breast and ovarian cancer, liver cancer methylation markers and their uses
Awarded China Patent
Methylation for diagnosis of stem cell carcinoma and lung cancer methylation markers, methylation markers for cancer diagnosis methylation markers for cancer diagnosis
Liver Cancer NMPA Registry Check Completed
The world's first company to pass the IVD registration test for liver cancer methylation detection in China
First to initiate Chinese NMPA liver cancer clinical trial
Received a major project from the Ministry of Science and Technology of China
Jointly develop screening standards and technical routes for liver cancer, bowel cancer and lung cancer in the Chinese population
Completion of NMPA China liver cancer clinical trial
Release of NMPA clinical trial data for liver cancer
Passed PCR laboratory acceptance
Multi-omics for early screening of bowel cancer Blood product sizing
Commercialization of liver cancer products in China
Officially launched the LDT test for liver cancer in China Scale up commercialization
Pan-cancer early screening multi-omics Blood product marker screening
Early screening LDT product launch for five cancer types
LAMH MR Liver Cancer Recurrence Surveillance Program Launched at Lyman Health
LAMH was recognized as one of the first "National High-tech Enterprises" in 2022
莱盟健康LAMH MR肝癌复发监测项目启动
Latest News
Cutting-edge cooperation
Stanford Medicine
Johns Hopkins
Harvard Medical School
Cleveland Clinic
UCI Rvine
Uc San Diego
Purdue University
University Of Arizona
U Health
Moffitt Cancer Center
Ochsner Health
Cedars Sinai
Listed in no particular order
《Nature Materials》
The researchers performed ctDNA methylation model analysis on 1098 liver cancer patients and 835 normal human samples, and established a comprehensive methylation diagnostic model (AUC: 0.969) and a comprehensive prognostic model with high sensitivity and specificity by targeted methylation sequencing method to screen 10 and 8 methylation sites for real-time tumor load detection, treatment response, recurrence monitoring and prognostic assessment. The comprehensive diagnostic model has higher sensitivity and specificity in stage I, II, and III tumors compared to the AFP assay, which does not vary much in other stages of liver cancer except for stage III and IV.
Read more
Using NGS technology, the study conducted artificial intelligence training on methylation data of 3,771 samples from three databases of TCGA and Chinese clinical samples to screen specific methylation models for four common cancers (breast cancer, colorectal cancer, liver cancer, and lung cancer). The validation results showed that the methylation models achieved over 95% accuracy in detecting the four cancers in the Chinese population.
Read more
《Nature Communications》
Current methods for quantitative methylation analysis do not take into account the heterogeneity of cells at the time of sequencing, which can lead to poor correlation between methylation analysis results and gene expression data. the CHALM algorithm helps us to better reveal the function of DNA methylation and its association with gene expression.
Read more
《Nature Materials》
HelioLiver Test, a blood test combining cfDNA methylation patterns with tumor protein markers for analysis, achieved a sensitivity of 85% for detection of liver cancer and 76% for early stage (AJCC stages I and II), as well as a specificity of 91% in a double-blind, multicenter clinical validation study collecting 122 patients with liver cancer and 125 patients with cirrhosis, with significantly better detection performance than AFP and GALAD models.
Read more